TISIDB

Summary
Symbol	MAT1A
Name	methionine adenosyltransferase I, alpha
Aliases	MATA1; SAMS1; S-adenosylmethionine synthetase; MAT 1; MAT-I/III; S-adenosylmethionine synthetase isoform typ ......
Chromosomal Location	10q22
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	-
Domain	PF02773 S-adenosylmethionine synthetase PF02772 S-adenosylmethionine synthetase PF00438 S-adenosylmethionine synthetase
Function	Catalyzes the formation of S-adenosylmethionine from methionine and ATP. The reaction comprises two steps that are both catalyzed by the same enzyme: formation of S-adenosylmethionine (AdoMet) and triphosphate, and subsequent hydrolysis of the triphosphate.

> Gene Ontology [ TOP ]
Biological Process	GO:0000096 sulfur amino acid metabolic process GO:0001887 selenium compound metabolic process GO:0006520 cellular amino acid metabolic process GO:0006555 methionine metabolic process GO:0006556 S-adenosylmethionine biosynthetic process GO:0006730 one-carbon metabolic process GO:0006732 coenzyme metabolic process GO:0006790 sulfur compound metabolic process GO:0009063 cellular amino acid catabolic process GO:0009066 aspartate family amino acid metabolic process GO:0009068 aspartate family amino acid catabolic process GO:0009087 methionine catabolic process GO:0009108 coenzyme biosynthetic process GO:0016054 organic acid catabolic process GO:0032259 methylation GO:0044272 sulfur compound biosynthetic process GO:0044282 small molecule catabolic process GO:0046395 carboxylic acid catabolic process GO:0046500 S-adenosylmethionine metabolic process GO:0051186 cofactor metabolic process GO:0051188 cofactor biosynthetic process GO:0051259 protein oligomerization GO:0051260 protein homooligomerization GO:0051262 protein tetramerization GO:0051289 protein homotetramerization GO:1901565 organonitrogen compound catabolic process GO:1901605 alpha-amino acid metabolic process GO:1901606 alpha-amino acid catabolic process
Molecular Function	GO:0004478 methionine adenosyltransferase activity GO:0016765 transferase activity, transferring alkyl or aryl (other than methyl) groups GO:0098601 selenomethionine adenosyltransferase activity
Cellular Component	-

> KEGG and Reactome Pathway [ TOP ]
KEGG	hsa00270 Cysteine and methionine metabolism hsa01100 Metabolic pathways hsa01230 Biosynthesis of amino acids
Reactome	R-HSA-211859: Biological oxidations R-HSA-1430728: Metabolism R-HSA-71291: Metabolism of amino acids and derivatives R-HSA-2408508: Metabolism of ingested SeMet, Sec, MeSec into H2Se R-HSA-156581: Methylation R-HSA-156580: Phase II conjugation R-HSA-2408522: Selenoamino acid metabolism R-HSA-1614635: Sulfur amino acid metabolism

Summary
Symbol	MAT1A
Name	methionine adenosyltransferase I, alpha
Aliases	MATA1; SAMS1; S-adenosylmethionine synthetase; MAT 1; MAT-I/III; S-adenosylmethionine synthetase isoform typ ......
Chromosomal Location	10q22
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between MAT1A and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining [ TOP ]
There is no record.

Summary
Symbol	MAT1A
Name	methionine adenosyltransferase I, alpha
Aliases	MATA1; SAMS1; S-adenosylmethionine synthetase; MAT 1; MAT-I/III; S-adenosylmethionine synthetase isoform typ ......
Chromosomal Location	10q22
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of MAT1A in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	NA/NS	NA/NS
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	NA/NS	NA/NS
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	MAT1A
Name	methionine adenosyltransferase I, alpha
Aliases	MATA1; SAMS1; S-adenosylmethionine synthetase; MAT 1; MAT-I/III; S-adenosylmethionine synthetase isoform typ ......
Chromosomal Location	10q22
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of MAT1A in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	0.956	0.228
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	0.173	0.903
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	1.542	0.158
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	-1.591	0.0169
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	-2.346	0.023
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	-0.649	0.595
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	0.048	0.962
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	1.323	0.377
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	-1.374	0.388
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	-0.266	0.876
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	0.119	0.957
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	-0.179	0.605

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of MAT1A in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/Res	% Mut/NRes	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	0	0	0	1
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	0	0	0	1
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	0	0	0	1
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	0	1.4	-1.4	1
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	0	0	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	0	1.7	-1.7	1
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	9.5	5.9	3.6	1
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	12.5	0	12.5	1
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	7.7	9.1	-1.4	1
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0	0	0	1
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0	0	0	1
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0	0	0	1
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	0	3.7	-3.7	0.415
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	0	7.7	-7.7	0.371
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	0	0	0	1
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	0	0	0	1
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	0	0	1

Summary
Symbol	MAT1A
Name	methionine adenosyltransferase I, alpha
Aliases	MATA1; SAMS1; S-adenosylmethionine synthetase; MAT 1; MAT-I/III; S-adenosylmethionine synthetase isoform typ ......
Chromosomal Location	10q22
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of MAT1A. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	MAT1A
Name	methionine adenosyltransferase I, alpha
Aliases	MATA1; SAMS1; S-adenosylmethionine synthetase; MAT 1; MAT-I/III; S-adenosylmethionine synthetase isoform typ ......
Chromosomal Location	10q22
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of MAT1A. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by MAT1A. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	MAT1A
Name	methionine adenosyltransferase I, alpha
Aliases	MATA1; SAMS1; S-adenosylmethionine synthetase; MAT 1; MAT-I/III; S-adenosylmethionine synthetase isoform typ ......
Chromosomal Location	10q22
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of MAT1A. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	MAT1A
Name	methionine adenosyltransferase I, alpha
Aliases	MATA1; SAMS1; S-adenosylmethionine synthetase; MAT 1; MAT-I/III; S-adenosylmethionine synthetase isoform typ ......
Chromosomal Location	10q22
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of MAT1A expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	MAT1A
Name	methionine adenosyltransferase I, alpha
Aliases	MATA1; SAMS1; S-adenosylmethionine synthetase; MAT 1; MAT-I/III; S-adenosylmethionine synthetase isoform typ ......
Chromosomal Location	10q22
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between MAT1A and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	MAT1A
Name	methionine adenosyltransferase I, alpha
Aliases	MATA1; SAMS1; S-adenosylmethionine synthetase; MAT 1; MAT-I/III; S-adenosylmethionine synthetase isoform typ ......
Chromosomal Location	10q22
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting MAT1A collected from DrugBank database.

> Drugs from DrugBank database

[ TOP ]

Details on drugs targeting MAT1A.

ID	Name	Drug Type	Targets	#Targets
DB00118	Ademetionine	Small Molecule	AMD1, AS3MT, CBS, CMTR1, COMT, GNMT, MAT1A, MAT2A	8
DB03191	3-Oxiran-2ylalanine	Small Molecule	MAT1A	1
DB03611	L-2-amino-4-methoxy-cis-but-3-enoic acid	Small Molecule	MAT1A	1

Browse MAT1A